Results 1 to 10 of about 278,146 (249)
Chronic lymphocytic leukemia [PDF]
Cancer, 1978 Chronic lymphocytic leukemia (CLL) is the commonest type of leukemia seen in Western countries. It affects an older group of individuals than most other varieties of leukemia, and men more often than women, in a ratio of 2:1. The incidence of CLL is significantly increased in some families.
R. Wayne Rundles, Joseph O. Moore
openalex +4 more sources
Chronic Lymphocytic Leukemia [PDF]
Cancers, 2020 This Special Issue of Cancers, made up of nine articles (four original papers, four reviews, and a brief report), is dedicated to chronic lymphocytic leukemia (CLL) [...]
Vaisitti T., Arruga F., Ferrajoli A.
openaire +6 more sources
Chronic Lymphocytic Leukemia [PDF]
Hematology, 2002 Abstract This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our
Kay, Neil E. +7 more
+9 more sources
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Blood, 2021 Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study (NCT04746092) was to determine the efficacy of COVID-19 vaccine in patients with CLL.
Y. Herishanu +12 more
semanticscholar +1 more source
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
New England Journal of Medicine, 2023 BACKGROUND Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. METHODS In a phase
B. Eichhorst +49 more
semanticscholar +1 more source
Chronic Lymphocytic Leukemia [PDF]
HemaSphere, 2018 AbstractCLL is a rare indication for HCT/Cellular Therapy since it usually follows an indolent course. Allogeneic HCT is considered as standard of care in eligible high-risk patients who have failed at least two classes of modern pathway inhibitor-based therapy, and in select patients with CLL transformed in to an aggressive B-cell lymphoma (Richter ...
Johannes Schetelig, Peter Dreger
+9 more sources
Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival [PDF]
, 2015 Leukemic cells from Chronic Lymphocytic Leukemia (CLL) patients interact with stromal cells of the surrounding microenvironment. Mesenchymal Stromal Cells (MSCs) represent the main population in CLL marrow stroma, which may play a key role for disease ...
Ave, Elisa +15 more
core +7 more sources
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
American journal of hematology/oncology, 2021 Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course.
M. Hallek, O. Al-Sawaf
semanticscholar +1 more source
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
New England Journal of Medicine, 2022 BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic ...
Jennifer R. Brown +27 more
semanticscholar +1 more source